Samsung Epis (A0126Z0) Q1 2026 earnings summary

Executive summary

• Achieved consolidated revenue of 454B KRW and operating profit of 91B KRW in Q1 2026, with Bioepis contributing 455B KRW in revenue and 144B KRW in operating profit, up 14% and 13% year-over-year, respectively.

• Operates as a pure holding company with two main subsidiaries focused on biosimilar and next-generation bio-platform technologies.

• Revenue growth driven by solid product sales, new launches, milestone recognition from SB4 EU commercial right extension, and major global partnerships.

• Expanded biosimilar portfolio with direct commercialization in EU and US, global patent settlements, and robust R&D pipeline advancing biosimilar and novel drug candidates.

• Strengthened strategic partnerships and open innovation initiatives to secure new growth drivers.

Financial highlights

• Q1 2026 consolidated revenue: 454B KRW (up from 251.7B KRW in prior period); Bioepis Q1 2026 revenue: 455B KRW (+14% YoY, +6% QoQ); operating profit: 144B KRW (+13% YoY, +393% QoQ); OPM: 32%.

• Holdings consolidated operating profit: 91B KRW; net profit: 99.5B KRW; Bioepis net profit: 122B KRW.

• EBITDA for Holdings: 191B KRW; for Bioepis: 166B KRW.

• Gross profit for Holdings: 240B KRW; for Bioepis: 291B KRW; gross margin: 52.8%.

• Cash and cash equivalents at period end: 113.5B KRW.

Outlook and guidance

• Maintains FY26 guidance of 10%+ product revenue growth, targeting total revenue of 1,850B KRW.

• Continued expansion in biosimilar markets expected as major biologic patents expire globally, with new launches and R&D in ADC and obesity therapeutics to drive growth.

• Strategic focus on global partnerships and licensing to diversify revenue streams.